I can't comment on the least mean squared numbers, but will say this. The releases I have read, have been straight forward, very easy to understand and never misleading.
If you don't understand the difference between a primary and a secondary end point, or a trial that has been stated by the company to most likely be 1 of 2 required.... Its got to be your interpretation of the results that is causing you grief, and I would be careful taking advise from people on this chat board to try and read between the lines.
Ann: Rexlemestrocel-L Improves LVEF, Preceding Reduction in MACE, page-139
-
- There are more pages in this discussion • 161 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.31 |
Change
-0.010(0.76%) |
Mkt cap ! $1.495B | |||
| Open | High | Low | Value | Volume |
| $1.31 | $1.33 | $1.28 | $1.819M | 1.396M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 29972 | $1.31 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.31 | 2008 | 1 |
View Market Depth
| Last trade - 16.10pm 01/11/2024 (20 minute delay) ? |
| MSB (ASX) Chart |